BofA/Merrill published its Top 10 U.S. Ideas Quarterly for Q3 that identifies companies it sees having significant catalysts in the next three months. The list includes eight Buys and two Underperforms. The Buys are Applied Materials (AMAT), Boise Cascade (BCC), Burlington Stores (BURL), Comcast (CMCSA), Comerica (CMA), Eli Lilly (LLY), Facebook (FB), and International Game (IGT). The Underperforms are BlackBerry (BBRY) and PBF Energy (PBF).

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here

UBS analyst Erika Najarian lowered the firm's price target on Comerica to $55 from $59 and keeps a Neutral rating on the shares. Despite the company's liability sensitive positioning, management reiterated the 2024 net interest income outlook for a decline of 11% year over year which is now based on two 25 basis point cuts, the analyst tells investors in a research note. The firm continues to view the NII outlook as a "show me" story given the uncertainty surrounding the macro-economic backdrop, and while there are attractive drivers to the 2025 outlook, including the roll-off of interest rate swaps, repricing in the securities book and tailwinds from lower deposit costs, success in 2025 is predicated on the 2024 exit point, UBS argues.

Morgan Stanley named Comcast as the firm's "Top Pick in the Cable & Satellite" industry and notes that it remains the firm's only Overweight-rated name in the sector. Shares are now down 10% year-to-date despite a stable earnings outlook, says the analyst, who remains confident Comcast can grow broadband ARPU consistent with its historical 3%-4% range in 2024 and beyond. Moderating losses at Peacock and the opening of its new theme park Epic Universe in 2025 should also contribute to consolidated EBITDA growth, the analyst tells investors.

Reports Q1 CET1 capital ratio 12.01%. Reports Q1 net charge-offs .1%. "Today we reported first quarter earnings per share of $0.98," said Curtis Farmer, Comerica chairman and CEO. "Strategic rationalization efforts from 2023 and favorable pipeline trends position us for growth. Deposits outperformed normal seasonal patterns as we added new customers and expanded existing relationships while maintaining pricing discipline. Our liquidity strategy remained a highlight as we normalized our cash position, significantly reduced wholesale funding and successfully executed a record $1.0 billion debt issuance. We experienced ongoing, expected credit normalization, while net charge-offs of 10 basis points continued to be historically low. We are committed to running an efficient organization as we navigate expense pressures and execute on the action plans announced last quarter. Conservative capital management and lower loan balances further enhanced our capital position and drove our estimated CET1 ratio to 11.47, well above our 10% target."

Shares of sleep apnea device makers ResMed (RMD) and Inspire Medical (INSP) are moving in opposite directions after Eli Lilly (LLY) announced topline results of the SURMOUNT-OSA Phase 3 clinical trials, showing tirzepatide injection significantly reduced the apnea-hypopnea index, or AHI, compared to placebo, achieving the primary endpoints of the studies. After initially moving... To see the rest of the story go to thefly.com. See Story Here

Shares of sleep apnea device makers ResMed (RMD) and Inspire Medical (INSP) are slipping in early trading after Eli Lilly (LLY) announced topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection significantly reduced the apnea-hypopnea index, or AHI, compared to placebo, achieving the primary endpoints of the studies. SURMOUNT-OSA Study 1 evaluated tirzepatide, which Lilly identifies as "the only approved GIP and GLP-1 treatment for chronic weight management, commercialized as Zepbound in the U.S. and Mounjaro in some global markets outside the U.S.," in adults with moderate-to-severe obstructive sleep apnea, or OSA, and obesity who were not on positive airway pressure, or PAP, therapy for 52 weeks. In Wednesday pre-market trading, ResMed shares are down about 3% to $180, while Inspire shares have slipped about 1% to $220.